Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia

Citation metadata

From: The New England Journal of Medicine(Vol. 337, Issue 4)
Publisher: Massachusetts Medical Society
Document Type: Article
Length: 79 words

Document controls

Main content

Abstract :

Interferon alfa-2b combined with cytarabine seems more beneficial than interferon alfa-2b alone in the treatment of chronic myelogenous leukemia. Researchers randomly assigned 360 leukemia patients to take both drugs and 361 to take interferon alfa-2b alone. Three years after treatment began, survival rates were 86% in the combination treatment group and 79% in the interferon alfa-2b group. Forty-one percent of the patients taking both drugs had responded within 1 year, compared to 24% of those taking interferon alfa-2b alone.

Source Citation

Source Citation   

Gale Document Number: GALE|A19636857